The Valley Desk

NCT03623243 · Interventional trial

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Overall registry status Completed

Phase 3

Conditions Advancing Multiple Sclerosis, Multiple Sclerosis, Relapsing Multiple Sclerosis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov